These findings might provide mechanistic explanation for the pathogenesis in synovial sarcoma, and suggested that targeting IL-17A/IL-17R pathway was a novel promising strategy to treat patients with synovial sarcoma. This evidence concerns the gene IL17RA and synovial sarcoma.